Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132547 · ClinicalTrials.gov registry record · Phase 3
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
A Phase 3 study, sponsored by University of South Florida.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT01132547: Clinical Trial Phase 3 study, sponsored by University of South Florida.
NCT01132547 is a Phase 3 study that was terminated before completion, run by University of South Florida. The registered enrollment target is 22 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01132547, a Phase 3 study, was terminated before completion, sponsored by University of South Florida.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial is studying cyproheptadine hydrochloride to see how well it works in preventing weight loss in young patients receiving chemotherapy for cancer.
Interventions
- OTHER placebo
- DRUG cyproheptadine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Why NCT01132547 stopped before completion
NCT01132547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01132547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01132547 about?
NCT01132547 is a clinical study titled "Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer". RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial i...
What is the current status of trial NCT01132547?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2010-06. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01132547?
The interventions under investigation include: placebo (OTHER), cyproheptadine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01132547?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01132547's enrollment target sits among peer trials
22 1953rd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia